It has been improving the share of secured loans in the loan book over the past few years. Its loan book is spread across multiple states with a lesser geographical concentration. Given these factors and a reasonable valuation, investors with a long-term view may consider the IPO.
Biocon shares rise 2% on 10-year Pertuzumab supply deal for breast cancer therapy in Brazil
Biocon shares rose after the company secured a 10-year Pertuzumab supply contract in Brazil. The consortium with Bahiafarma and Bionovis received full allocation under the